Evidence map›Paper›PMID 34688260›Full record

ArticleBMC cancer2021

Identification of C3 and FN1 as potential biomarkers associated with progression and prognosis for clear cell renal cell carcinoma.

Yang Dong, Wei-Ming Ma, Wen Yang, Lin Hao, Shao-Qi Zhang, Kun Fang, Chun-Hui Hu, Qian-Jin Zhang, Zhen-Duo Shi, Wen-da Zhang and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. New insights into fibrotic signaling in renal cell carcinoma.Frontiers in cell and developmental biology · 2023
    Review
  12. Article
  13. Article
  14. Inside-Out of Complement in Cancer.Frontiers in immunology · 2022
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Yang Dong *Department of Urology, Xuzhou Central Hospital, Xuzhou, China.
Wei-Ming Ma *Department of Urology, Xuzhou Central Hospital, Xuzhou, China.
Wen Yang *Department of Nephrology, The First Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan, China.
Lin Hao *Department of Urology, Xuzhou Central Hospital, Xuzhou, China.
Shao-Qi ZhangNanjing University of Traditional Chinese Medicine, Nanjing, China.
Kun FangDepartment of Nephrology, The First Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan, China.
Chun-Hui HuDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Qian-Jin ZhangDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Zhen-Duo ShiDepartment of Urology, Xuzhou Central Hospital, Xuzhou, China.
Wen-da ZhangDepartment of Urology, Xuzhou Central Hospital, Xuzhou, China.
Tao FanDepartment of Urology, Xuzhou Central Hospital, Xuzhou, China.
Tian XiaDepartment of Urology, Xuzhou Central Hospital, Xuzhou, China.
Cong-Hui HanDepartment of Urology, Xuzhou Central Hospital, Xuzhou, China. hanchdoctor@st.btbu.edu.cn.
Xuzhou Central Hospital · CNSoochow University · CNShandong First Medical University · CNAffiliated Hospital of Shandong Academy of Medical Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is one of the most lethal urological malignancies, but the pathogenesis and prognosis of ccRCC remain obscure, which need to be better understand.

methodsDifferentially expressed genes were identified and function enrichment analyses were performed using three publicly available ccRCC gene expression profiles downloaded from the Gene Expression Omnibus database. The protein-protein interaction and the competing endogenous RNA (ceRNA) networks were visualized by Cytoscape. Multivariate Cox analysis was used to predict an optimal risk mode, and the survival analysis was performed with the Kaplan-Meier curve and log-rank test. Protein expression data were downloaded from Clinical Proteomic Tumor Analysis Consortium database and Human Protein Atlas database, and the clinical information as well as the corresponding lncRNA and miRNA expression data were obtained via The Cancer Genome Atlas database. The co-expressed genes and potential function of candidate genes were explored using data exacted from the Cancer Cell Line Encyclopedia database.

resultsOf the 1044 differentially expressed genes shared across the three datasets, 461 were upregulated, and 583 were downregulated, which significantly enriched in multiple immunoregulatory-related biological process and tumor-associated pathways, such as HIF-1, PI3K-AKT, P53 and Rap1 signaling pathways. In the most significant module, 36 hub genes were identified and were predominantly enriched in inflammatory response and immune and biotic stimulus pathways. Survival analysis and validation of the hub genes at the mRNA and protein expression levels suggested that these genes, particularly complement component 3 (C3) and fibronectin 1 (FN1), were primarily responsible for ccRCC tumorigenesis and progression. Increased expression of C3 or FN1 was also associated with advanced clinical stage, high pathological grade, and poor survival in patients with ccRCC. Univariate and multivariate Cox regression analysis qualified the expression levels of the two genes as candidate biomarkers for predicting poor survival. FN1 was potentially regulated by miR-429, miR-216b and miR-217, and constructed a bridge to C3 and C3AR1 in the ceRNA network, indicating a critical position of FN1.

conclusionsThe biomarkers C3 and FN1 could provide theoretical support for the development of a novel prognostic tool to advance ccRCC diagnosis and targeted therapy.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellDisease ProgressionFibronectinsHumansKidney NeoplasmsSurvival AnalysisBiomarkers, TumorFibronectinsFN1 protein, humanBiomarkerClear cell renal cell carcinomaComplement component 3Fibronectin 1Prognostic value

Identifiers

PMID34688260
PMCPMC8539775
OpenAlexW3208608272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.